It’s just one week to our annual fall biotech event—where the founders and lead investors of three of Boston’s hottest companies share their stories of trying to build great companies out to make a real difference in people’s health.
The event is called Boston’s Life Science Disruptors. And in this case, the stories are from three upstarts that all have gone public in the past year and a half—Epizyme (NASDAQ: [[ticker:EPZM]]), Sage Therapeutics (NASDAQ: [[ticker:SAGE]]), and Zafgen (NASDAQ: [[ticker:ZFGN]]). This trio of small companies is taking on some very big problems—cancer, central nervous system disorders, and obesity, respectively—all in unique ways. You can read more details about each in this post by my colleague Ben Fidler.
Our event takes place at Novartis Institutes for Biomedical Research in Cambridge on the evening of Wednesday, October 8. We only have a handful of tickets left as of this writing—and they are going fast.
The agenda showing how this interactive evening will play out has just been posted. We’ve also added one new speaker, Carl Goldfischer, managing director of Bay City Capital, one of the lead investors in Epizyme. Goldfischer will join Epizyme CEO Robert Gould on stage to tell the company’s story.
The pair will be part of a star-studded lineup that also includes Peter Barrett and Bruce Booth of Atlas Venture; Zafgen CEO Tom Hughes; Sage CEO Jeffrey Jonas; and Third Rock Ventures’ Kevin Starr. We’ll also have a short opening talk from Martin Seidel, the global head of strategic alliances at the Novartis Institutes.
You can find out more details, and get your tickets on our event page. Tickets are likely to sell out soon—so get yours now. We hope to see you on Oct. 8.